Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4947 |
Name | cholangiocarcinoma |
Definition | A bile duct adenocarcinoma that has_material_basis_in bile duct epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5249 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer bile duct cancer bile duct carcinoma bile duct adenocarcinoma cholangiocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600X | Vemurafenib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | Infigratinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 mutant | Infigratinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion FGFR2 V564F | Infigratinib | cholangiocarcinoma | predicted - resistant | detail... |
IDH1 mutant | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
FGFR2 fusion | Futibatinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 rearrange | Futibatinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 rearrange FGFR2 amp | Futibatinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 rearrange | Pemigatinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 mutant | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR3 mutant | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | Pemigatinib | cholangiocarcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | cholangiocarcinoma | predicted - sensitive | detail... |
IDH1 R132C | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
IDH1 R132S | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
IDH1 R132L | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
IDH1 R132G | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
FGFR3 amp | Infigratinib | cholangiocarcinoma | no benefit | detail... |
FGFR2 amp | Infigratinib | cholangiocarcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | ICP-192 | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 rearrange | Infigratinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 M537I FGFR2 V564L FGFR2 amp | Infigratinib | cholangiocarcinoma | predicted - resistant | detail... |
IDH1 R132H | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
IDH1 R132S | Ceralasertib + Olaparib | cholangiocarcinoma | sensitive | detail... |
FGFR2 C382R | Pemigatinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | Lirafugratinib | cholangiocarcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | cholangiocarcinoma | sensitive | detail... |
BRAF V600E | Cobimetinib + Vemurafenib | cholangiocarcinoma | predicted - sensitive | detail... |
IDH1 R132C | Olaparib | cholangiocarcinoma | no benefit | detail... |
IDH1 R132C | Pamiparib | cholangiocarcinoma | no benefit | detail... |
IDH1 R132C | Niraparib | cholangiocarcinoma | no benefit | detail... |
ARID1B Q127_Q131del IDH1 R132L | Niraparib | cholangiocarcinoma | no benefit | detail... |
ARID1B Q127_Q131del IDH1 R132L | Olaparib | cholangiocarcinoma | no benefit | detail... |
ARID1B Q127_Q131del IDH1 R132L | Pamiparib | cholangiocarcinoma | no benefit | detail... |
MLH1 negative | Pembrolizumab | cholangiocarcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | cholangiocarcinoma | sensitive | detail... |
FGFR2 I291_Y308del | Pemigatinib | cholangiocarcinoma | predicted - sensitive | detail... |
BRAF V600E | BGB3245 | cholangiocarcinoma | predicted - sensitive | detail... |
IDH1 act mut | LY3410738 | cholangiocarcinoma | predicted - sensitive | detail... |
IDH2 act mut | LY3410738 | cholangiocarcinoma | predicted - sensitive | detail... |
IDH1 mutant | Durvalumab + Olaparib | cholangiocarcinoma | no benefit | detail... |
FGFR2 C382R | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 act mut | Tinengotinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 Y375C | Futibatinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 H167_N173del | Infigratinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 N631_M640del | Infigratinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 I548Wfs*8 | Infigratinib | cholangiocarcinoma | sensitive | detail... |
FGFR2 I288_D304del | Infigratinib | cholangiocarcinoma | no benefit | detail... |
FGFR2 C382R | Infigratinib | cholangiocarcinoma | no benefit | detail... |
FGFR2 K545del | Infigratinib | cholangiocarcinoma | no benefit | detail... |
FGFR2 S372C | Lenvatinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | E7090 | cholangiocarcinoma | predicted - sensitive | detail... |
MLH1 negative | Nivolumab | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 C382R | Tinengotinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 I291_Y308del FGFR2 N549K | Pemigatinib | cholangiocarcinoma | predicted - resistant | detail... |
FGFR2 C382R FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564L | Pemigatinib | cholangiocarcinoma | predicted - resistant | detail... |
ATM G1676fs | Talazoparib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR1 rearrange | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 rearrange | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR3 rearrange | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
FGFR2 fusion | Gemcitabine + Pemigatinib | cholangiocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01438554 | Phase I | Pazopanib + Trametinib | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DNK | DEU | 0 |
NCT01825603 | Phase I | ADH-1 + Cisplatin + Gemcitabine | ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01888302 | Phase I | Cisplatin + Gemcitabine + Sirolimus | Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery | Completed | USA | 0 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
NCT02053376 | Phase II | Regorafenib | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | Completed | USA | 0 |
NCT02128282 | Phase Ib/II | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Silmitasertib | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | Completed | USA | 2 |
NCT02150967 | Phase II | Infigratinib | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Terminated | USA | ITA | GBR | ESP | DEU | BEL | 5 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02232633 | Phase II | Amcasertib | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | Completed | CAN | 0 |
NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | ROU | POL | ITA | BGR | 0 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | DNK | 0 |
NCT02452970 | Phase II | RRx-001 Cisplatin + Gemcitabine | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) | Terminated | USA | 0 |
NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated | USA | 1 |
NCT02508467 | Phase I | Fisogatinib | A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CHE | 5 |
NCT02520141 | Phase II | Ramucirumab | Ramucirumab for Advanced Pre-treated Biliary Cancers | Completed | USA | 0 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | POL | NOR | NLD | ITA | ISR | FRA | ESP | DNK | DEU | BRA | AUS | 9 |
NCT02632305 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel | A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) | Active, not recruiting | CAN | 0 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02711553 | Phase II | Ramucirumab Merestinib Cisplatin + Gemcitabine | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | USA | TUR | SWE | HUN | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG | 4 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | DNK | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02856568 | Phase I | Cisplatin + Gemcitabine + Ricolinostat | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma | Withdrawn | USA | 0 |
NCT02924376 | Phase II | Pemigatinib | Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | BEL | 4 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT02982720 | Phase II | Peginterferon alfa-2b + Pembrolizumab | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | Terminated | USA | 0 |
NCT02989857 | Phase III | Ivosidenib | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | Completed | USA | ITA | GBR | FRA | ESP | 1 |
NCT03093870 | Phase II | Capecitabine + Varlitinib Capecitabine | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | Completed | USA | POL | HUN | ESP | AUS | 6 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS | 2 |
NCT03132792 | Phase I | AFPc332T | AFPc332T in Advanced HCC | Active, not recruiting | USA | GBR | FRA | ESP | 0 |
NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | BEL | 0 |
NCT03201458 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
NCT03212274 | Phase II | Olaparib | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | 0 |
NCT03230318 | Phase II | Derazantinib | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) | Completed | USA | ITA | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL | 1 |
NCT03250273 | Phase II | Entinostat + Nivolumab | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT03257761 | Phase I | Durvalumab + Guadecitabine | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | Active, not recruiting | USA | 0 |
NCT03267940 | Phase I | Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Gemcitabine + PEGPH20 Cisplatin + Gemcitabine + PEGPH20 | Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | Terminated | USA | 2 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03339843 | Phase II | Abemaciclib | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) | Completed | FRA | BEL | 0 |
NCT03368963 | Phase Ib/II | Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Recruiting | USA | 0 |
NCT03377179 | Phase II | ABC294640 | A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma | Completed | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03656536 | Phase III | Pemigatinib Cisplatin + Gemcitabine | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302) | Active, not recruiting | USA | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUT | 2 |
NCT03704480 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) | Active, not recruiting | FRA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03773302 | Phase III | Cisplatin + Gemcitabine Infigratinib | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 6 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG | 6 |
NCT03872947 | Phase I | Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT03878095 | Phase II | Ceralasertib + Olaparib | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | Active, not recruiting | USA | 0 |
NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03943004 | Phase I | DFP-14927 | Trial of DFP-14927 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04003636 | Phase III | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) | Active, not recruiting | USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
NCT04003896 | Phase II | Abemaciclib | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy | Terminated | USA | 0 |
NCT04034238 | Phase I | LMB-100 + Tofacitinib | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
NCT04057365 | Phase II | DKN-01 + Nivolumab | A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | Terminated | USA | 0 |
NCT04068194 | Phase Ib/II | Avelumab Avelumab + Peposertib | Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Recruiting | USA | 0 |
NCT04088188 | Phase I | Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | Terminated | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |
NCT04149691 | Phase I | CPL304110 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Recruiting | POL | 0 |
NCT04175912 | Phase II | Carboplatin + MLN4924 + Paclitaxel MLN4924 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | Active, not recruiting | USA | 0 |
NCT04233567 | Phase II | Infigratinib | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | Active, not recruiting | USA | 0 |
NCT04294576 | Phase I | BJ-001 + Pembrolizumab BJ-001 | Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) | Active, not recruiting | USA | 0 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
NCT04306367 | Phase II | Olaparib + Pembrolizumab | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | Active, not recruiting | USA | 0 |
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT04421820 | Phase I | BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Recruiting | USA | IRL | CAN | 1 |
NCT04430738 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Active, not recruiting | USA | 1 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04507503 | Expanded access | Futibatinib | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | Approved for marketing | USA | 0 |
NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | AUS | 5 |
NCT04565275 | Phase Ib/II | ICP-192 | A Study of ICP-192 in Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT04641871 | Phase I | Sym021 + Sym023 Sym021 + Sym022 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | FRA | ESP | CAN | 0 |
NCT04645160 | Phase Ib/II | Tivozanib | Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma | Recruiting | USA | 0 |
NCT04648319 | Phase II | Nivolumab | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Terminated | LUX | LBN | BEL | 0 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04676633 | Phase I | Cotsiranib | Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy | Completed | USA | 0 |
NCT04677504 | Phase II | Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | Completed | USA | TUR | POL | ITA | GBR | ESP | 7 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04781192 | Phase Ib/II | Durvalumab + Regorafenib | The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers | Recruiting | USA | 0 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
NCT04919642 | Phase II | Tinengotinib | Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma | Completed | USA | 0 |
NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Active, not recruiting | USA | GBR | ESP | 0 |
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |
NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS | 5 |
NCT05176665 | Phase Ib/II | EMB-01 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | Recruiting | USA | 1 |
NCT05194072 | Phase I | SGN-B7H4V | A Study of SGN-B7H4V in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 0 |
NCT05211323 | Phase II | Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine | A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer | Active, not recruiting | USA | 0 |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Terminated | USA | 0 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Terminated | USA | GBR | AUS | 0 |
NCT05244551 | Phase I | ABSK061 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05275478 | Phase Ib/II | TNG908 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT05411133 | Phase I | ARB202 + Atezolizumab ARB202 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | Recruiting | AUS | 1 |
NCT05506943 | Phase II | Paclitaxel CTX-009 + Paclitaxel | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers | Active, not recruiting | USA | 0 |
NCT05510427 | Phase I | Atezolizumab + Bevacizumab + Infigratinib | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | Withdrawn | 0 | |
NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUS | 5 |
NCT05568680 | Phase I | SynKIR-110 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Recruiting | USA | 0 |
NCT05615818 | Phase III | Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib | Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) | Recruiting | GBR | FRA | BEL | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05694715 | Phase I | Irinotecan + Niraparib | Combination Therapy in Cancers With Mutations in DNA Repair Genes | Recruiting | USA | 0 |
NCT05712356 | Phase II | CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) | Recruiting | USA | ESP | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05727176 | Phase II | Futibatinib | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4) | Recruiting | USA | POL | ITA | ESP | BRA | AUS | ARG | 5 |
NCT05784688 | Phase Ib/II | Pembrolizumab + TU2218 | Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05848843 | Phase I | Adagrasib + Durvalumab | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | USA | 0 |
NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Recruiting | USA | CAN | 0 |
NCT05874414 | Phase Ib/II | GNS561 + Trametinib | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma | Recruiting | USA | 1 |
NCT05876754 | Phase III | Ivosidenib | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe) | Recruiting | SWE | ROU | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 2 |
NCT05921760 | Phase Ib/II | Ipilimumab + Ivosidenib + Nivolumab | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | Active, not recruiting | USA | GBR | 0 |
NCT05948475 | Phase III | Tinengotinib | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308) | Recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 3 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT05967182 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT06178445 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab + Trastuzumab | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC) | Recruiting | DEU | 0 |
NCT06178588 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06282575 | Phase III | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + ZW25 Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + ZW25 Cisplatin + Gemcitabine + ZW25 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Recruiting | USA | SWE | ROU | ITA | ISR | FRA | FIN | ESP | CAN | ARG | 8 |
NCT06302621 | Phase I | Afatinib + Pemigatinib | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06341764 | Phase II | Cisplatin + Durvalumab + Gemcitabine + Tremelimumab | Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma | Recruiting | ITA | 0 |
NCT06360354 | Phase I | AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel | A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion | Recruiting | USA | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 2 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06400485 | Phase I | AMT-676 | AMT-676 in Patients With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT06439485 | Phase II | Atezolizumab + Bevacizumab + Pemigatinib | Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | Not yet recruiting | USA | 0 |
NCT06440993 | Phase II | Cisplatin + Durvalumab + Gemcitabine | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | Recruiting | DEU | 0 |
NCT06441747 | Phase II | Durvalumab + Olaparib | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | Not yet recruiting | AUS | 0 |
NCT06597721 | Phase I | AMT-754 | AMT-754 in Patients With Selected Advanced Solid Tumours | Not yet recruiting | AUS | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |